Revolution Medicines, Inc.
RVMD
Rang in Aktien
#579
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Aktienkurs
$195.46
Marktkapitalisierung
$41.89B
Veränderung (1 Tag)
7.31%
Veränderung (1 Jahr)
261.90%
Land
US
Handel Revolution Medicines, Inc. (RVMD)
Kategorie
Healthcare
P/B-Verhältnis für Revolution Medicines, Inc. (RVMD)
P/B-Verhältnis zum October 2026 TTM: 15.66
Laut den neuesten Finanzberichten und dem Aktienkurs von Revolution Medicines, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 15.66. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 1.78.
P/B-Verlauf für Revolution Medicines, Inc. von 2017 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 15.66 | 383.31% |
| 2024 | 3.24 | 82.27% |
| 2023 | 1.78 | -36.60% |
| 2022 | 2.80 | -7.84% |
| 2021 | 3.04 | -45.25% |
| 2020 | 5.55 | -19.62% |
| 2019 | 6.91 | -36.63% |
| 2018 | 10.91 | -95.31% |
| 2017 | 232.64 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | -60.08% |
US
|
|
| 13.2547 | -15.36% |
US
|
|
| 4.208 | -73.13% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.52% |
NL
|
